Health technology company Royal Philips announced the release of Transcend Plus, its EPIQ CVx and Affiniti CVx cardiovascular ultrasound systems.
Transcend Plus features FDA-cleared 2D- and 3D-image quality enhancements, as well as a suite of AI-enabled clinical applications.
According to the company, Transcend Plus improves sharpness, contrast and detail in 2D and 3D imaging, including the latest FDA-cleared enhancements for EPIQ CVx and Affiniti CVx.
In addition, the upgrades support visualization of cardiac anatomy and function, allowing diagnostic confidence even in complicated or technically challenging cases, according to the company.
The update also includes a new 2D Auto EF Advanced feature that expands AI capabilities for contrast images, considered essential for accurately evaluating cardiac function.
The integration also provides more actionable insights, which can reduce delays and support timely, evidence-based clinical decisions.
"Building on the momentum of our original Transcend launch, Transcend Plus brings the full power of AI integration to the forefront, giving clinicians the confidence, speed and precision they need to lead in cardiac care, today and into the future," David Handler, business leader of cardiology ultrasound at Philips, said in a statement.
THE LARGER TREND
In July, Royal Philips announced it received FDA 510(k) clearance for its image-guided navigation system for prostate cancer. The UroNav system features an annotation workflow that supports clinicians during prostate biopsies and focal therapy procedures.
It fuses diagnostic MRI images of the prostate with live ultrasound images for guided procedures in real time. The aim is to help deliver more precise, minimally invasive care.
Additionally, Philips UroNav offers compatibility with ultrasound devices and needle guides, improved privacy and security tools, and integration with Philips DynaCAD systems for radiology and urology.
That same month, Royal Philips and Indonesia's Ministry of Health announced plans to deploy image-guided therapy systems, as part of their signed agreements, under the Strengthening Indonesia’s Healthcare Referral Network (SIHREN) project.
The aim of the initiative is to transform the country’s treatment for heart disease, stroke and cancer by expanding access to technologies and care.
In March, Royal Philips expanded its partnership with Ibex Medical Analytics that included a release of the Philips IntelliSite Pathology Solution (PIPS) to speed up adoption of AI-enabled digital pathology tools.
That same month, Royal Philips joined forces with Ingeborg Initiatives, a maternal health company, to provide expectant parents in Arkansas with access to the Philips Avent Pregnancy+ app with personalized information provided by the state and tools to increase access to care.
The aim of the partnership is to enhance health literacy and encourage users to embrace healthy habits.
